EP2073820A4 - Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels - Google Patents

Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels

Info

Publication number
EP2073820A4
EP2073820A4 EP07842578.2A EP07842578A EP2073820A4 EP 2073820 A4 EP2073820 A4 EP 2073820A4 EP 07842578 A EP07842578 A EP 07842578A EP 2073820 A4 EP2073820 A4 EP 2073820A4
Authority
EP
European Patent Office
Prior art keywords
binding segments
containing multifunctional
prodrugs containing
targeted polymer
multifunctional binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07842578.2A
Other languages
German (de)
English (en)
Other versions
EP2073820A2 (fr
Inventor
Hong Zhao
Maria Belen Rubio
Prasanna Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belrose Pharma Inc
Original Assignee
Belrose Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belrose Pharma Inc filed Critical Belrose Pharma Inc
Publication of EP2073820A2 publication Critical patent/EP2073820A2/fr
Publication of EP2073820A4 publication Critical patent/EP2073820A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C08G73/12—Unsaturated polyimide precursors
    • C08G73/121—Preparatory processes from unsaturated precursors and polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20—General preparatory processes
    • C08G64/26—General preparatory processes using halocarbonates
    • C08G64/28—General preparatory processes using halocarbonates and phenols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
EP07842578.2A 2006-09-15 2007-09-15 Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels Withdrawn EP2073820A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84494306P 2006-09-15 2006-09-15
PCT/US2007/078600 WO2008034124A2 (fr) 2006-09-15 2007-09-15 Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels

Publications (2)

Publication Number Publication Date
EP2073820A2 EP2073820A2 (fr) 2009-07-01
EP2073820A4 true EP2073820A4 (fr) 2014-07-16

Family

ID=39184644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07842578.2A Withdrawn EP2073820A4 (fr) 2006-09-15 2007-09-15 Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels

Country Status (11)

Country Link
EP (1) EP2073820A4 (fr)
JP (1) JP2010503708A (fr)
KR (1) KR20090057383A (fr)
CN (1) CN101541332A (fr)
AU (1) AU2007296056B2 (fr)
BR (1) BRPI0716812A2 (fr)
CA (1) CA2662981A1 (fr)
IL (1) IL197517A0 (fr)
MX (1) MX2009002855A (fr)
RU (1) RU2009114154A (fr)
WO (1) WO2008034124A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131208A1 (fr) 2007-04-20 2008-10-30 Enzon Pharmaceuticals, Inc. Adénosine désaminase recombinante stable
US8586019B2 (en) 2008-05-22 2013-11-19 Ramot At Tel-Aviv University Ltd. Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
EP2303288A4 (fr) 2008-05-22 2015-04-22 Univ Ramot Conjugués d'un polymère, d'un bisphosphonate et d'un agent anti-angiogenèse et leurs utilisations dans le traitement et la surveillance de maladies concernant les os
WO2009143412A2 (fr) * 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d’oligonucléotides
MX2011000861A (es) 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
CA2742838A1 (fr) * 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Lipides-polymeres liberables pour systemes de delivrance d'acides nucleiques
EP2362729A1 (fr) * 2008-11-17 2011-09-07 Enzon Pharmaceuticals, Inc. Conjugués libérables pour systèmes d'administration d'acides nucléiques
WO2011089215A1 (fr) * 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
WO2011130599A1 (fr) * 2010-04-16 2011-10-20 Enzon Pharmaceuticals, Inc. Conjugués polymères d'analogues d'adénine nucléosides
US20130096097A1 (en) 2010-06-11 2013-04-18 Japan Science And Technology Agency Pharmaceutical multimeric particles, and manufacturing method for same
WO2012075087A2 (fr) * 2010-11-30 2012-06-07 Board Of Trustees Of The University Of Illinois Conjugués de nanoparticule de silice-agent
CN103045720B (zh) * 2011-10-17 2014-08-20 格诺思博生物科技(上海)有限公司 检测病源细胞的靶向性分子及其应用
CN104244988A (zh) 2012-03-05 2014-12-24 雷蒙特亚特特拉维夫大学有限公司 结合治疗活性剂的聚合物、其制备方法以及其用途
CN102731518B (zh) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药
CN102746316B (zh) * 2012-06-26 2015-04-15 济南精合医药科技有限公司 用于抗肿瘤药物的间硝基芳甲氧基喜树碱缺氧激活前药
MX371201B (es) * 2013-10-04 2020-01-22 Prolynx Llc Conjugados de liberación lenta de sn-38.
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201414098D0 (en) * 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
EP3218009B1 (fr) 2014-10-14 2021-04-07 Polytherics Limited Procédé pour la conjugaison d'un peptide ou d'une protéine avec un réactif comprenant un groupe partant comportant une partie de peg
BR112017005760A2 (pt) * 2014-10-24 2017-12-12 Polytherics Ltd conjugados e reagentes de conjugação
JP6570034B2 (ja) * 2014-11-26 2019-09-04 日本化薬株式会社 新規なグルタミン酸誘導体およびその用途
CN105641708A (zh) * 2014-12-04 2016-06-08 上海中医药大学附属普陀医院 多肽修饰的聚(甲基丙烯酸寡聚乙二醇酯-co-蟾毒灵)纳米制剂及其制备方法
JP6772199B2 (ja) * 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
CN107375288B (zh) * 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
CN106265683A (zh) * 2016-09-14 2017-01-04 江南大学 一种具有穿膜靶向特性的致病菌生物膜新型抑制剂的制备方法
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
KR102279429B1 (ko) 2017-04-21 2021-07-20 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 멀티 암 표적 항암 콘쥬게이트
JP7231147B2 (ja) * 2017-06-29 2023-03-01 国立大学法人東海国立大学機構 Ｒｎａ導入試薬及びその利用
KR102762352B1 (ko) * 2017-11-30 2025-02-05 씨젠 인크. 약물 링커 화합물의 제조방법
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
MX2020007442A (es) 2018-01-12 2020-09-14 Prolynx Llc Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
KR102141124B1 (ko) * 2018-01-30 2020-08-04 (주)바이오니아 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도
KR20200134287A (ko) * 2018-04-02 2020-12-01 젠켐 테크놀로지 컴퍼니 리미티드 (베이징) 타겟성을 구비하는 세포막 투과 펩타이드-다중팔 폴리에틸렌글리콜-약물 켤레체 및 그 응용
CN113365664A (zh) * 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
BR112021005320A2 (pt) * 2018-12-17 2021-06-15 Remegen Co., Ltd. ligante para conjugados de anticorpo-fármaco e seu uso
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
AU2021319279A1 (en) * 2020-07-28 2023-02-23 Chongqing Upgra Biotechnology Co., Ltd. Polyethylene glycol conjugate drug, and preparation method therefor and use thereof
EP4190360A1 (fr) * 2020-07-28 2023-06-07 Chongqing Upgra Biotechnology Co., Ltd. Agent synergiste de médicament conjugué au polyéthylène glycol, son procédé de préparation et son utilisation
JP2024500994A (ja) 2020-12-28 2024-01-10 デボル，インコーポレイテッド タンパク質及び多官能化変性ポリエチレングリコール系架橋剤を含む反応性乾燥粉末状止血用材料
CA3198230A1 (fr) * 2021-01-28 2022-08-04 Jian Chen Conjugue et son utilisation
EP4471005A4 (fr) * 2022-01-24 2025-11-19 Beijing Chempion Biotechnology Co Ltd Conjugué et son utilisation
WO2025139993A1 (fr) * 2023-12-29 2025-07-03 四川科伦博泰生物医药股份有限公司 Conjugué anticorps-médicament, composition pharmaceutique associée et utilisation associée
CN118994301B (zh) * 2024-08-13 2025-04-01 广州医科大学 一种中药小分子偶联化合物及其在耐药性肿瘤中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
WO2003093346A1 (fr) * 2002-05-06 2003-11-13 Universita' Degli Studi Di Trieste Derives de polyethyleneglycol multifonctionnels, leur preparation et utilisation
WO2004014424A1 (fr) * 2002-08-13 2004-02-19 Enzon, Inc. Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
WO2004110358A2 (fr) * 2003-05-15 2004-12-23 Vectramed, Inc. Conjugues polymeres pour administration de medicaments a activation tissulaire
WO2006084089A2 (fr) * 2005-02-04 2006-08-10 Enzon Pharmaceuticals, Inc. Procede de preparation de conjugues polymeres

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2626654B2 (ja) * 1990-03-31 1997-07-02 科学技術振興事業団 標的指向性高分子医薬化合物及びその中間体
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
EP0979102A4 (fr) * 1997-04-30 2005-11-23 Enzon Inc Polypeptides a chaine unique modifies par oxyde de polyalkylene
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US7060479B2 (en) * 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6214330B1 (en) * 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
ATE378342T1 (de) * 2001-02-20 2007-11-15 Enzon Inc Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
CN100475269C (zh) * 2002-03-05 2009-04-08 北京键凯科技有限公司 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途
NZ542687A (en) * 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US8012488B2 (en) * 2005-02-18 2011-09-06 Nof Corporation Polyoxyalkylene derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
WO2003093346A1 (fr) * 2002-05-06 2003-11-13 Universita' Degli Studi Di Trieste Derives de polyethyleneglycol multifonctionnels, leur preparation et utilisation
WO2004014424A1 (fr) * 2002-08-13 2004-02-19 Enzon, Inc. Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
WO2004110358A2 (fr) * 2003-05-15 2004-12-23 Vectramed, Inc. Conjugues polymeres pour administration de medicaments a activation tissulaire
WO2006084089A2 (fr) * 2005-02-04 2006-08-10 Enzon Pharmaceuticals, Inc. Procede de preparation de conjugues polymeres

Also Published As

Publication number Publication date
WO2008034124A3 (fr) 2008-08-07
RU2009114154A (ru) 2010-10-20
BRPI0716812A2 (pt) 2013-11-05
AU2007296056B2 (en) 2012-09-13
KR20090057383A (ko) 2009-06-05
CN101541332A (zh) 2009-09-23
CA2662981A1 (fr) 2008-03-20
JP2010503708A (ja) 2010-02-04
AU2007296056A1 (en) 2008-03-20
MX2009002855A (es) 2009-03-30
EP2073820A2 (fr) 2009-07-01
WO2008034124A2 (fr) 2008-03-20
IL197517A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
EP2073820A4 (fr) Promédicaments polymères ciblés contenant des segments de liaison multifonctionnels
BRPI0716253A2 (pt) glioxalaÇço de polÍmero de vinilamida
EP2088170A4 (fr) Composition de résine
EP2089308A4 (fr) Distributeur
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
EP2004735A4 (fr) Polymères activés de liaison à des molécules biologiques
ES2527265T8 (es) Consola
BRPI0716823A2 (pt) Conjunto poliméricos contendo porções positivamente carregadas
BRPI0715704A2 (pt) dispensador de lenÇos quadrilongo
BRPI0718313A2 (pt) Conjunto de cateter
BRPI0718796A2 (pt) Nucleotídeo
PT2180901E (pt) Purificação de conjugados utilizando hidroxiapatite
DE602007012549D1 (de) Vulkanisat enthaltend azin-funktionalisiertes polymer
DE602007011183D1 (de) Hydrazinfunktionalisiertes Polymer
BRPI0815246A2 (pt) Composição de catalisador
BRPI0718428A2 (pt) Composição de ibuprofeno
BRPI0716458A2 (pt) Composição de vulcanizado
EP2192914A4 (fr) Liants polymères contenant des groupes disulfures de pyridyle
EP1988081A4 (fr) Inhibiteur de liaison de sphingosine-1-phosphate
EP2048201A4 (fr) Composition de résine
BRPI0720097A2 (pt) Compostos de fosfonato
DE602007000552D1 (de) Abgasreinigungskatalysator
ZA200808289B (en) Modified molecules which promote hematopoiesis
BRPI0718141A2 (pt) Composições de frangrâncias
ZA200900927B (en) Glyoxalation of vinylmide polymer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090415

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101AFI20090707BHEP

Ipc: A61K 38/16 20060101ALI20090707BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BELROSE PHARMA INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20140617

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101AFI20140611BHEP

Ipc: A61K 38/16 20060101ALI20140611BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150515